CA2348536A1 - Radiodense compositions - Google Patents

Radiodense compositions Download PDF

Info

Publication number
CA2348536A1
CA2348536A1 CA002348536A CA2348536A CA2348536A1 CA 2348536 A1 CA2348536 A1 CA 2348536A1 CA 002348536 A CA002348536 A CA 002348536A CA 2348536 A CA2348536 A CA 2348536A CA 2348536 A1 CA2348536 A1 CA 2348536A1
Authority
CA
Canada
Prior art keywords
composition
radiodense
radiation
compound
target tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002348536A
Other languages
English (en)
French (fr)
Inventor
Gregory L. Mcintire
Edward R. Bacon
Kathleen J. Illig
Gerald L. Wolf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare AS
General Hospital Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9909799.0A external-priority patent/GB9909799D0/en
Application filed by Individual filed Critical Individual
Publication of CA2348536A1 publication Critical patent/CA2348536A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1085—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy characterised by the type of particles applied to the patient
    • A61N2005/1091—Kilovoltage or orthovoltage range photons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Radiation-Therapy Devices (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
CA002348536A 1998-10-29 1999-10-29 Radiodense compositions Abandoned CA2348536A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US18316698A 1998-10-29 1998-10-29
US09/183,166 1998-10-29
US13141899P 1999-04-28 1999-04-28
GBGB9909799.0A GB9909799D0 (en) 1999-04-28 1999-04-28 Method
US60/131,418 1999-04-28
GB9909799.0 1999-04-28
PCT/US1999/025529 WO2000025829A2 (en) 1998-10-29 1999-10-29 Radiodense compositions

Publications (1)

Publication Number Publication Date
CA2348536A1 true CA2348536A1 (en) 2000-05-11

Family

ID=27269711

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002347915A Abandoned CA2347915A1 (en) 1998-10-29 1999-10-29 Enhanced radiation therapy
CA002348536A Abandoned CA2348536A1 (en) 1998-10-29 1999-10-29 Radiodense compositions

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA002347915A Abandoned CA2347915A1 (en) 1998-10-29 1999-10-29 Enhanced radiation therapy

Country Status (5)

Country Link
EP (2) EP1124580A1 (ja)
JP (2) JP2003520192A (ja)
AU (2) AU1710600A (ja)
CA (2) CA2347915A1 (ja)
WO (2) WO2000025829A2 (ja)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6493570B1 (en) 1998-11-02 2002-12-10 Photogen, Inc. Method for improved imaging and photodynamic therapy
US7390668B2 (en) 1996-10-30 2008-06-24 Provectus Pharmatech, Inc. Intracorporeal medicaments for photodynamic treatment of disease
US6331286B1 (en) 1998-12-21 2001-12-18 Photogen, Inc. Methods for high energy phototherapeutics
US8974363B2 (en) 1997-12-11 2015-03-10 Provectus Pharmatech, Inc. Topical medicaments and methods for photodynamic treatment of disease
AU1710600A (en) * 1998-10-29 2000-05-22 General Hospital Corporation, The Enhanced radiation therapy
US6986740B2 (en) 1998-11-02 2006-01-17 Xantech Pharmaceuticals, Inc. Ultrasound contrast using halogenated xanthenes
US8470296B2 (en) 1998-12-21 2013-06-25 Provectus Pharmatech, Inc. Intracorporeal medicaments for high energy phototherapeutic treatment of disease
US7384623B1 (en) 1998-12-21 2008-06-10 Provectus Pharmatech, Inc. High energy phototherapeutic agents
DE102008034020A1 (de) 2008-07-16 2010-01-21 Bayer Schering Pharma Aktiengesellschaft Kontrastmittel verstärkte Strahlentherapie mit Hochleistungsröhren
DE102010052613A1 (de) * 2010-11-29 2012-05-31 Stefan Brühl Verfahren zur Erhöhung der biologischen Wirkung von Röntgenstrahlen
WO2015134845A1 (en) * 2014-03-07 2015-09-11 Stc.Unm Quantitatively describing biophysical markers

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5008907A (en) * 1989-05-31 1991-04-16 The Regents Of The University Of California Therapy x-ray scanner
ATE195432T1 (de) * 1993-06-02 2000-09-15 Bracco Spa Iodierte paramagnetische chelaten, und deren verwendung als kontrastmittel
US5665330A (en) * 1995-02-08 1997-09-09 Nano Systems Llc Dual purposed diagnostic/therapeutic agent having a tri-iodinated benzoyl group linked to a coumarin
DE19627309C2 (de) * 1996-06-27 1999-07-29 Schering Ag Wäßrige injizierbare Formulierungen verwendbar als Kontrastmittel
WO1998047532A1 (en) * 1997-04-24 1998-10-29 Nycomed Imaging As Embolus therapy using insoluble microparticles or vesicles containing contrast agents
AU1710600A (en) * 1998-10-29 2000-05-22 General Hospital Corporation, The Enhanced radiation therapy
AR022404A1 (es) * 1999-01-25 2002-09-04 Photogen Inc Metodo y agentes para la terapia de radiacion mejorada

Also Published As

Publication number Publication date
EP1126884A2 (en) 2001-08-29
AU1601700A (en) 2000-05-22
AU1710600A (en) 2000-05-22
WO2000025829A3 (en) 2000-11-30
JP2003520192A (ja) 2003-07-02
WO2000025819A1 (en) 2000-05-11
JP2002528521A (ja) 2002-09-03
EP1124580A1 (en) 2001-08-22
WO2000025829A2 (en) 2000-05-11
CA2347915A1 (en) 2000-05-11
WO2000025819A9 (en) 2000-09-21

Similar Documents

Publication Publication Date Title
Ju et al. Inherent multifunctional inorganic nanomaterials for imaging-guided cancer therapy
Lee et al. Nano‐sized CT contrast agents
Krause Delivery of diagnostic agents in computed tomography
EP1848464B1 (en) Compositions and methods for multimodal imaging
AU2011278308B2 (en) Nanoparticle-guided radiotherapy
US5676928A (en) Liposomes
Deagostino et al. Insights into the use of gadolinium and gadolinium/boron-based agents in imaging-guided neutron capture therapy applications
CA2348536A1 (en) Radiodense compositions
AU2016349577A1 (en) Long-lived gadolinium based tumor targeted imaging and therapy agents
US20040258744A1 (en) Blood-pool carrier for lipophilic imaging agents
CHENG et al. The production and evaluation of contrast-carrying liposomes made with an automatic high-pressure system
Zielhuis et al. Lanthanide bearing microparticulate systems for multi-modality imaging and targeted therapy of cancer
US20040047804A1 (en) Enhanced radiation therapy
WHITE et al. Biodistribution and clearance of contrast-carrying MREV liposomes
CA2212162A1 (en) Liposomes that contain contrast media for the visualization of intravascular space
EP0973553A2 (en) Blood-pool carrier for lipophilic imaging agents
WO1998052617A2 (en) Contrast media for imaging of lung draining lymph nodes, administered through the lungs
US20080241061A1 (en) Methods of imaging employing chelating agents
Patronas et al. Brain-tumor imaging using radiopaque perfluorocarbon: A preliminary report
Cruje Lanthanide Nanoparticles as Contrast Agents for In Vivo Dual Energy Microcomputed Tomography of the Mouse Vasculature
Perkins et al. Nanoengineered multimodal contrast agent for medical image guidance
Sachse Iodinated liposomes as contrast agents
Wang et al. Advanced Materials for the Delivery of Anti‐Cancer Compounds and Imaging Contrast Agents
KR20220095107A (ko) 산화철 자성 입자
SELTZER et al. Selective drug delivery systems

Legal Events

Date Code Title Description
FZDC Discontinued application reinstated
EEER Examination request
FZDE Discontinued
FZDE Discontinued

Effective date: 20061030